C
IGMS

Covestor’s IGM Biosciences IGMS Stock Holding History

Covestor’s Portfolio IGMS Stock Details IGMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-8
Closed – – 2260
2021
Q4 		$0 Buy
+8
New +$398 ﹤0.01% 2201

Other funds holding IGMS

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Covestor's IGMS Position: Q1 2022 in Review

Covestor sold out of IGM Biosciences (IGMS) in Q1 2022, closing a stake of 8 shares.

Covestor first reported a position in IGMS in Q4 2021 and held it in 1 quarter. The position peaked at $0 in Q4 2021. 93 funds tracked by Wall St. Rank hold IGMS as of Q1 2022.

  • Covestor reported no remaining IGM Biosciences position as of Q1 2022 after selling out during the quarter.
  • Covestor sold 8 IGM Biosciences shares in Q1 2022.
  • Covestor first reported a position in IGM Biosciences in Q4 2021 and held it in 1 quarter.
  • Covestor's IGM Biosciences position peaked at $0 in Q4 2021.
  • 93 funds tracked by Wall St. Rank held IGM Biosciences as of Q1 2022.

Based on Covestor's 13F filing for Q1 2022, filed 13 May 2022.